Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Transcript

May 27, 2019 / 02:30PM GMT
Operator

(technical difficulty)

during the conference. A recording of this conference call, including the Q&A session, will be available on our website shortly after the call ends. (Operator Instructions)

With that, I would like to hand over to Mr. Samir Shah, Global Head of Investor Relation. Please go ahead, sir.

Samir Shah
Novartis AG - Global Head of IR

Thank you very much, and thank you to all of you taking the time on a public holiday to actually participate in this conference call. With me, we have Vas Narasimhan, CEO of the group; Paul Hudson, CEO of Pharma; and Dave Lennon, Head of the AveXis group.

The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Please refer to the company's Form 20-F on file with the U.S. Securities and Exchange Commission for a description of some of these factors.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot